Newer BTK inhibitors like zanubrutinib is currently undergoing a phase 2 clinical trial in patients with lupus nephritis (NCT04643470), while BI-BTK-1 showed promising preclinical results in a murine model of lupus nephritis (23–25). This evidence concerns the gene BTK and lupus nephritis.